triazolam has been researched along with Fasting Hypoglycemia in 1 studies
Triazolam: A short-acting benzodiazepine used in the treatment of insomnia. Some countries temporarily withdrew triazolam from the market because of concerns about adverse reactions, mostly psychological, associated with higher dose ranges. Its use at lower doses with appropriate care and labeling has been reaffirmed by the FDA and most other countries.
Fasting Hypoglycemia: HYPOGLYCEMIA expressed in the postabsorptive state, after prolonged FASTING, or an overnight fast.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ambrosi, F | 1 |
| Ricci, S | 1 |
| Quartesan, R | 1 |
| Moretti, P | 1 |
| Pelicci, G | 1 |
| Pagliacci, C | 1 |
| Nicoletti, I | 1 |
1 other study available for triazolam and Fasting Hypoglycemia
| Article | Year |
|---|---|
Effects of acute benzodiazepine administration on growth hormone, prolactin and cortisol release after moderate insulin-induced hypoglycemia in normal women.
Topics: Adult; Female; Flurazepam; Growth Hormone; Humans; Hydrocortisone; Hypoglycemia; Hypothalamo-Hypophy | 1986 |